Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3897)	5/29/2001 1:35:58 PM
From: nigel bates	Read Replies (1) \| Respond to of 52153

Any comment on the Sequenom / Gemini deal ? Is this self serving hype - Paul Kelly, president and chief executive of Gemini, said increased scientific and commercial reach made sense for both firms as rivals race to exploit the potential of the human genome, which was sequenced last year. "There is a critical moment in genomics right now: we've got the human genome sequence but the real issue is how you convert it into drug and diagnostic targets," Kelly told Reuters. "There's only two or three years left to do it, and after that it will be too late...I think we are seeing the start of a wave of consolidation." - or is there a kernel of truth in it ? Are all targets really going to be either proprietary or in the public domain within three years ? That would certainly have implications for valuations in the sector... nig